Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by MrMonkon Jan 10, 2014 12:14am
171 Views
Post# 22076826

Update from Investor Relations

Update from Investor RelationsReceived the following note from DP today:

Insiders have been big buyers and a lot of the volume are
people close to the company, so hopefully that has cleaned the market up a lot. The asset is there and if gold starts to rise we should be in good
shape. Of course we know the big buyer the other day. The best thing to
mention is the latest review of historic assays means we likely have a
fourth deposit to tie in with the Marban, plus the drilling we did extended
the Norlartic deposit and will add resources at the Marban pit. All is good.


- MM
people close to the company, so hopefully that has cleaned the market up a
lot. The asset is there and if gold starts to rise we should be in good
shape. Of course we know the big buyer the other day. The best thing to
mention is the latest review of historic assays means we likely have a
fourth deposit to tie in with the Marban, plus the drilling we did extended
the Norlartic deposit and will add resources at the Marban pit. All is good.
<< Previous
Bullboard Posts
Next >>